Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib

J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.

Authors

Liang Zeng¹, Chen Xia¹, Yongchang Zhang², Nong Yang¹

Affiliations

¹ Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, People's Republic of China.
² Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, People's Republic of China. Electronic address: zhangyongchang@csu.edu.cn.

PMID: 30922580
DOI: 10.1016/j.jtho.2018.11.026

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics*
Adenocarcinoma of Lung / pathology
Afatinib / pharmacology
Afatinib / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Crizotinib / pharmacology
Crizotinib / therapeutic use*
ErbB Receptors / genetics
Exons
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Lung Neoplasms / pathology
Male
Middle Aged
Mutation

Substances

Antineoplastic Agents
Afatinib
Crizotinib
EGFR protein, human
ErbB Receptors